Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Want to see HK:0950 full AI Analyst Report?
Top Page
Lee's Pharmaceutical Holdings Limited
(0950)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$1.00
▼(-35.48% Downside)
Action:Reiterated
Date:06/18/26
The score is led by attractive valuation (low P/E and ~4% dividend yield) and a generally solid balance sheet with low leverage. These positives are tempered by inconsistent operating performance with 2025 margin pressure, volatile free cash flow, and technical signals that remain weak on a longer-term basis (below 100D/200D and negative MACD).
Positive Factors
Conservative leverage / strong balance sheet
Sustained low debt-to-equity (≈0.08–0.15) and rising equity create long-term financial flexibility. This reduces refinancing risk, supports investment in R&D/commercialization, and cushions the business through revenue cyclicality, preserving strategic optionality over months.
Negative Factors
Margin compression and uneven operating results
Visible margin squeeze (operating margin fell from ~8% to ~4%) signals pressure on pricing, higher costs, or product mix shifts. Persisting compression would erode reinvestment capacity and returns, making earnings less predictable over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage / strong balance sheet
Sustained low debt-to-equity (≈0.08–0.15) and rising equity create long-term financial flexibility. This reduces refinancing risk, supports investment in R&D/commercialization, and cushions the business through revenue cyclicality, preserving strategic optionality over months.
Read all positive factors
Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$630.05M
Dividend Yield2.92%
Average Volume (3M)5.40M
Price to Earnings (P/E)6.9
Beta (1Y)0.81
Revenue Growth2.57%
EPS Growth-1.27%
CountryHK
Employees1,022
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.14
Shares Outstanding588,835,300
10 Day Avg. Volume4,101,801
30 Day Avg. Volume5,400,283
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio8.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Established in 1994 and headquartered in Sha Tin, Hong Kong, Lee's Pharmaceutical Holdings Limited functions as an investment holding enterprise primarily engaged in the development, production, promotion, and sale of pharmaceutical goods, with a ...
How the Company Makes Money
Lee's Pharmaceutical makes money primarily by commercializing prescription pharmaceutical products. Key revenue streams typically include: (1) product sales revenue from medicines it markets in its target markets (notably Mainland China) through i...
Lee's Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.44B | 1.40B | 1.05B | 1.23B | 1.27B |
| Gross Profit | 729.56M | 753.36M | 551.31M | 770.75M | 806.28M |
| EBITDA | 198.04M | 260.87M | 193.05M | 229.06M | 2.13B |
| Net Income | 91.94M | 93.10M | 16.70M | 51.28M | 1.99B |
Balance Sheet | |||||
| Total Assets | 3.46B | 2.62B | 2.89B | 2.78B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 349.90M | 216.84M | 171.00M | 189.30M | 277.53M |
| Total Debt | 310.27M | 227.30M | 204.14M | 163.49M | 267.14M |
| Total Liabilities | 1.56B | 1.07B | 930.07M | 939.50M | 1.25B |
| Stockholders Equity | 2.05B | 1.65B | 2.04B | 1.92B | 2.46B |
Cash Flow | |||||
| Free Cash Flow | 101.35M | 34.45M | -49.63M | 69.81M | -160.04M |
| Operating Cash Flow | 332.90M | 242.01M | 110.08M | 283.63M | 210.68M |
| Investing Cash Flow | -235.76M | -190.23M | -145.22M | -256.05M | -370.28M |
| Financing Cash Flow | 35.58M | -1.96M | 13.44M | -128.60M | 60.97M |
Lee's Pharmaceutical Holdings Limited Technical Analysis
Negative
1.55
Price Trends
1.11
Negative
1.25
Negative
1.55
Negative
Market Momentum
-0.01
Negative
46.87
Neutral
29.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.11, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 29.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0950.
Lee's Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$735.47M | 8.05 | 12.80% | 7.52% | -9.66% | 16.17% | |
69 Neutral | HK$2.07B | 7.19 | 12.91% | 15.40% | -1.88% | 17.57% | |
64 Neutral | HK$630.05M | 6.86 | 4.85% | 2.92% | 2.57% | -1.27% | |
52 Neutral | HK$727.87M | -58.55 | -3.34% | ― | -15.98% | 93.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$362.17M | -26.45 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$163.16M | -3.83 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:0950
Lee's Pharmaceutical Holdings Limited
1.07
-0.30
-22.13%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.02
-4.41%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.16
-33.70%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.99
0.67
209.37%
HK:0239
Pak Fah Yeow International Limited
2.36
0.06
2.61%
HK:2633
Jacobson Pharma Corporation Limited
1.09
-0.39
-26.35%
Lee's Pharmaceutical Holdings Limited Corporate Events
Lee’s Pharmaceutical launches HK$50 million share buyback programme
Jun 16, 2026
Lee’s Pharmaceutical Holdings has launched a share repurchase programme under an existing shareholder mandate, allowing it to buy back up to HK$50 million of shares from the open market through mid-2027, subject to a 10% cap of issued share ...
Lee’s Pharm Wins Gates Foundation Funding for Infant Respiratory Drug Push
Jun 1, 2026
Lee’s Pharmaceutical Holdings Limited is a China-based biopharmaceutical company with over three decades of industry experience, operating an integrated platform that spans drug development, regulatory work, manufacturing and commercialisati...
Lee’s Pharmaceutical Wins Strong Shareholder Backing for Dividend, Board and Share Mandates at AGM
May 21, 2026
Shareholders of Lee’s Pharmaceutical Holdings Limited approved all 10 resolutions at the company’s annual general meeting held on 21 May 2026, including the adoption of the 2025 audited financial statements and the declaration of a fin...
Lee’s Pharma commits RMB25m to connected biotech partnership fund
May 11, 2026
Lee’s Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical company, operates through subsidiaries including Zhaoke Hefei to invest in and develop life and health, biotechnology and related industries. The group leverages capita...
Lee’s Pharmaceutical Sets 2026 AGM to Approve Results, Dividend and Capital Mandates
Apr 23, 2026
Lee’s Pharmaceutical Holdings Limited has convened its annual general meeting for 21 May 2026 in Hong Kong, where shareholders will review and approve the audited financial statements for the year ended 31 December 2025 and consider a final ...
Lee’s Pharmaceutical Declares Final Dividend for 2025
Mar 30, 2026
Lee’s Pharmaceutical Holdings Limited has declared a final ordinary dividend of HKD 0.023 per share for the financial year ended 31 December 2025, reinforcing its commitment to delivering cash returns to shareholders. The dividend, denominat...
Lee’s Pharmaceutical posts flat profit on higher costs, trims final dividend
Mar 30, 2026
Lee’s Pharmaceutical Holdings Limited reported a modest 2.6% increase in revenue to HK$1.44 billion for the year ended 31 December 2025, while gross profit slipped 3.2% to HK$729.6 million. Profit attributable to shareholders edged down 1.2%...
Lee’s Pharm Wins China Approval for Intrarosa, Bolstering Women’s Health Portfolio
Mar 25, 2026
Lee’s Pharmaceutical Holdings has secured Chinese regulatory approval for Intrarosa, a non-estrogen steroid therapy licensed from Cosette Pharmaceuticals for treating postmenopausal women with moderate to severe vulvovaginal atrophy symptoms...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.